SCHEMBL15024283

SCHEMBL15024283

Cc1nc2c(s1)CN(C(=O)Cn1nc(-c3ccc(OC(F)F)cc3)nc1-c1ccccc1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
GRM5 P41594 2/20 0.44
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 3/20 0.40
RAB9A P51151 3/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTT P42858 1/20 0.38
DPP8 Q6V1X1 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NR1H3 Q13133 4/20 0.35
NR1H2 P55055 1/20 0.35
AVPR1B P47901 2/20 0.35
NPC1 O15118 2/20 0.35
GAA P10253 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15024401 0.90 TSHR (0.47) TSHRGRM5KMT2AALDH1A1RAB9A
SCHEMBL15024545 0.88 GRM5 (0.52) TSHRGRM5KMT2AALDH1A1RAB9A
SCHEMBL15002309 0.85 GRM5 (0.44) GRM5KMT2AALDH1A1RAB9AMAPT
SCHEMBL15024232 0.84 GRM5 (0.59) TSHRGRM5KMT2AALDH1A1RAB9A
SCHEMBL15024525 0.83 TSHR (0.44) TSHRGRM5KMT2AALDH1A1RAB9A
SCHEMBL15024268 0.83 GRM5 (0.61) TSHRGRM5KMT2AALDH1A1MAPT
SCHEMBL15002334 0.79 GRM5 (0.41) GRM5ALDH1A1RAB9ADPP8KDM4E
SCHEMBL15024381 0.79 RAB9A (0.47) TSHRGRM5KMT2AALDH1A1RAB9A
SCHEMBL15024311 0.78 TSHR (0.56) TSHRKMT2AALDH1A1RAB9ALMNA
SCHEMBL15024269 0.78 GRM5 (0.53) TSHRGRM5KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788333-B1 1,2,4-TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA BOEHRINGER INGELHEIM INT (DE) 2016-03-23 EP disclosed
US-8642774-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-04 US disclosed
US-8642774-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-04 US disclosed
WO-2013083741-A1 1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 WO disclosed
US-20130150341-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed
US-20130150341-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150341-A1 NOVEL COMPOUNDS GRM5, GRM1, GRIK5 TSHR 971/4885GRM5 1/4885KMT2A 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.